Severe Aseptic Meningitis with Hydrocephalus Following Iotrolan Myelography: a Case Report

Total Page:16

File Type:pdf, Size:1020Kb

Severe Aseptic Meningitis with Hydrocephalus Following Iotrolan Myelography: a Case Report 대 한 방 사 선 의 학 회 지 1993 ; 29 (3) : 391 ~393 Journal of Korean Radiological Society, May, 1993 Severe Aseptic Meningitis with Hydrocephalus Following Iotrolan Myelography: A Case Report Jae Hyoung Kim, M.D., Choong Kun Ha, M.D.*, In Oak Ahn, M.D. Dψartmeη t 0/ Diagnostic Radiology, Gyeongsang National University, College 0/ Medicine - Abstract- A case of severe aseptic meningitis with communicating hydrocephalus following iotrolan myelography is presented. The patient’s condition improved veη quickly after corticosteroid therapy. Rapid improvement and absence of pathogenic organisms in the CSF cu\ture strongly favor an aseptic meningitis. This is the first re­ ported case of aseptic meningitis with the secondaη development of hydrocephalus caused by iotrolan myelography Index Words: Contrast media, complications 10.448 Myelography, complications 30.446, 30.1222 Aseptic meningitis as a complication of derwent cervica1 myelography using lumbar myelography has been reported verγ rarely (1 -3) puncture technique because of persistent pares­ since metrizamide was replaced with new non­ thesia in both upper extremities. Before instilla­ ionic contrast media such as iopamid이, iohexol tion of 15ml of iotrolan (Isovist, Schering AG, and iotrolan, Iotrolan is a new contrast medium Berlin; 240mg Ij ml), the patient did not have with a non-ionic dimer of triiodinated benzene any signs or symptoms of meningitis. The cere­ ring. Recently we have experienced a severe brospinal fluid (CSF) obtained during the proce­ aseptic meningitis with hydrocephalus developed dure was c1ear. Mter myelography, the patient after iotrolan myelography. Only one case of rested in a supined position with the head elevat­ 0 mild aseptic meningitis associated with iotrolan ed 15-30 • myelography was reported in 1991 (4). This is Next morning after myelography, the patient the first reported case of aseptic meningitis with complained of headache, high fever (40 0 C) and the secondarγ development of hydrocepha1us neck stiffness. Over the next severa1 hours he de­ caused by these new non-ionic contrast media. veloped loss of bilateral pupillarγ light reflexes, left herniparesis and increased deep tendon re­ CASE REPORT flexes in a11 extremities, 없ld became drowsy Under the impression of iatrogenic bacterial A 49-year old man, who had a previous cervi- meningitis or aseptic meningitis, CT examination cal spina1 operation for C4j C5 dislocation, un- was performed, which showed a moderate degree *경상대학교 의과대 학 신경과학교실 * Department 0/ Neμ rology, Gyeongsaηg National University, College 0/ Medicine 이 논문은 199 2 년 11 월 17 일 접수하여 199 3 년 2 월 22 일에 채택되었음 . Received November 17, 1992, Accepted February 22, 1993 - 391 - Journal of Korean Radiological Society 1993 ; 29 (3) : 391 ~393 Fig. 1. CT scan one day after myelography shows moderate com­ municating hydrocephalus with obliteration of extracerebral sub­ archnoid spaces. Enhanced CT scans (not shown) showed no ab­ normal enhancement around basal Clsterns. Fig. 2. On CT scan seven days after myelography, hydrocephalus is decreased and extracerebral sub­ arachnoid spaces are well visual­ ized. 1 2 of communicating hydrocephalus with oblitera- phalus (Fig. 2) . tion of the extracerebral subarachnoid spaces (Fig. 1). A lumbar puncture was performed, and DISCUSSION the CSF appeared turbid and xanthochrornic. The CSF pressure was 200mm H 20 with non­ Hydrophilicity and osmolality of contrast physiologic Q-test. A WBC count was more than media are important factors in producing the 2000jml with 95% polymorphonuclear leukocyte, side effects associated with myelogarphy. Since with a protein level of 269 mgj dl, and glucose the advent of new non-ionic myelographic con­ level of 8mgj dl. After the cultures of CSF and trast media such as ioparnid이, iohexol and blood were done, we adrninistered both antibiot- iotrolan with high hydrophilicity and low ics and corticosteroid. osmolality, side effects after myelography have Two days later the patient markedly im­ been decreased. Iotrolan is highly hydrophilic proved; the mental status became alert, bilateral and has nearly the same osmolality as CSF and pupillaπ reflexes were normalized, and left blood in a concentration up to 30mg Ij ml, that herniparesis disappeared. Headache, rnild fever is , approximately half that of ioparnidol and and neck stiffness were still persistent. This dra­ iohexol. In regard to aseptic meningitis as a com­ matic clinical improvement led us to strongly plication of myelography, its exact cause is still consider the possibility of aseptic meningitis, and unknown although the toxic effect of contrast antibiotics was discontinued. media itself (6) and contrast media-induced im­ The results of CSF and blood cultures mune mechanism (5 ,7) have been suggested. showed no pathogenic organisms. The patient Sand et al mentioned that previously undergone was completely symptom-free seven days after myelography or spinal operation may be risk fac­ myelography when the CSF was clear and its tors concerning development of aseptic meningi­ pressure was 170mm H 20 with physiologic Q tis (6). However, their cases were too small for test. A WBC count was 42j ml with predorninant their concept to be accepted. Kelly et al de­ mononuclear leukocyte. The protein and glucose scribed that hydroce-phalus accompanying asep­ levels were within normal range. Follow-up CT tic menigitis was probably caused by immunologi­ exarnination performed seven days after myelo­ cally mediated generalized arachnoiditis (5) . graphy showed markedly decreased hydroce- Hydrocephalus is thought to be a result of severe …@ Jae Hyoung Kim , et al : Severe Aseptic Meningitis with Hydrocephalus Following lotrolan Myelography arachnoiditis in aseptic meningitis. fect of intrathecal iohexol on visual evoked Clinical features of aseptic meningitis are sim­ response latency: a comparison including inci­ ilar to those of bacterial meningitis following dence of headache with iopamidol and metri­ zamide in myeloradiculography. Clin Radiol 1987; myelography (8). Although, in general, symptoms 38:7_1-74 of bacterial meningitis often seem to occur later 2. Alexiou J , Deloffre D, Vandresse J-H, Boucquey (i.e. 24-96 hours) and persist longer than those J-p, Sintzoff S. Post-myelographic meningeal irri­ of aseptic meningitis (6), the differentiation be­ tation with iohexol. Neuroradiol 1991; 33:85-86 tween these two types of meningitis is difficult 3. Lee DK, Yi SD, Park YC. A case of aseptic puru­ both clinically and on the CSF profile. Only the lent meningitis complicationg Niopam CT result of CSF and blood cultures can make a dif­ cisternography. The Joumal of the Korean Neu­ ferential diagnosis. Therefore, rapid improve­ rological Association 1988; 6:78-82 ment of the patient’s condition and absence of 4. Nak와‘oshi T , Moriwaka F, Tashiro K, et al. Asep­ pathogenic organisms in the CSF, as in our case, tic meningitis complicating iotrolan myelography. AJNR 1991; 12:173 are in favor of aseptic meningitis. 5. Kelley RE, Daroff RB , Sheremata WA, McCor­ The effect of corticosteroid in treatment of mick JR. Unusual effects of metrizamide lumbar aseptic meningitis is not certain although a few myelography. constellation of aseptic meningitis, reports have described its effectiveness (5 ,7). It is arachnoiditis, communicating hydrocephalus, and usu꾀 ly recommended that all patients with asep­ Guillain-Barre syndrome. Arch Neurol 1980; 37: tic meningitis following myelography should ini­ 588-589 tially be treated with antibiotics until the result 6. Sand T, Anda S, Hellum K, Hesselberg JP, Dale of CSF culture is available (6). L. Chemical meningitis in metrizamide myelo­ Although the causative mechanism of aseptic garphy: report of seven cases. N euroradiol 1986; 28:69-71 meningitis following myelography is not certain, 7. Weissman BM. Delayed onset of dexamethasone­ iotrolan may cause severe aseptic meningitis and dependent cerebral dysfunction following metri­ the possibility of this complication should be kept zamide myelography. Arch Neurol 1984; 4 1: 569 in mind. 570 8. Schlesinger JJ, Salit IE, McCormack G. Strepto­ REFERENCES coccal meningitis after myelography. Arch Neurol 1982; 39:576-577 1. Broadbridge AT, Bayliss SG, Brayshaw CI. The ef- 〈국문 요약〉 lotrolan 척추강조영술 후 수두증을 동반한 중증 무균성 뇌막엽의 발생 : 증례 보고 경 상대학교 의과대학 진단방사선 과학교실 , 신경과학교실* 김 재 형 • 하 충 건 * . 안 인 옥 경추부 탈골 수술을 받은 49세 남자 환자에샤 Iotrolan 척추강조영술 후 발생한 수두증을 동반하는 중증 무균성 뇌막염 1 례를 보고한다. 환자는 척추강 시행 다음날 부터 갑작스런 고열, 뇌막자극 증후, 의식의 저하, 대광반사 소 실 및 건반사 증가 등의 소견을 나타냈으며 전산화단층촬영에서 뇌실 확장 소견을 보였다 . 뇌척수액은 전형적인 세 균성 뇌막염 소견을 보였으나 균은 동정되지 않았고 , 스테로이드 투여 후 1 일 만에 급 속한 상태 호전을 보여 무균성 뇌 막염 임 을 시 사하였다. 수두증을 동반한 무균성 뇌 막염 은 Me tri z amid e 를 재 외 하면 Iopamidol, Iohexol , Iotrolan 등이 사용된 이래로는 첫번째 보고이다 . n m ο 빙 국제방사선 종양학회 총회 장 소 : 일본 교또 기 간 : 93 년 6 월 21 일 -6월 25 일 제 8차 International Congress on the Ultrasonic Examination of the Breast 장 소 : Heidelberg( 독일) 기 간 : 93 년 7 월 1 일 -7월 4 일 문 의 : 연세의대 영동세브란스 오기근 교수 TEL: 569-0110( 교 3111, 2532) World Federation for ULS in Med. & Bio 장 소 : 일본 삿뽀로 기 간 : 93 년 7 월 17 일 -7월 22 일 20th Annual Refresher Course International Skeletal Society venue: Westin Harbour Cast!e Hote!, Toronto, CANAND contact : Dawne Rya!s, Rya!s and Associates, lnc. , P.O.Box 1925, Roswell, GA30077 -1925,USA.(Tel : 404 -641 -9773, Fax : 404-552 -9859 )1 993/8/ 18-21 E.C.R. 장 소 : 비엔나 기 간 : 93 년 9 월 12 일 -9월 17 일 International Diagnostic Radiology Conference 장 소 : Sa!zburg( 오스트리아) 기 간 : 93 년 9 월 19 일 -9월 24 일 N euroradiologicum 장 소:구마모또 기 간 : 93 년 9 월 25 일 - 10 월 1 일 ULS in Med. & Rad. 장 소 : lnsbruck( 오 스트리 아) 기 간 : 93 년 10 월 12 일 - 10 월 17 일 RSNA 장 소: 시카고 기 간 : 93 년 11 월 28 일 - 12 월 3 일 394 -.
Recommended publications
  • Intrathecal Gadolinium-Enhanced MR Cisternography in the Evaluation Of
    Intrathecal Gadolinium-Enhanced MR ORIGINAL RESEARCH Cisternography in the Evaluation of CSF Leakage H. Selcuk BACKROUND AND PURPOSE: Radiologic identification of the location of the CSF leakage is important S. Albayram for proper surgical planning and increases the chance of dural repair. This article describes our experience in analyzing clinically suspected cranial CSF fistulas by using MR imaging combined with H. Ozer the intrathecal administration of a gadolinium-based contrast agent. S. Ulus MATERIALS AND METHODS: A total of 85 consecutive patients with suspected CSF fistulas who G.Z. Sanus presented with persistent or intermittent rhinorrhea or otorrhea lasting for more than 1 month between M.Y. Kaynar 2003 and 2007 were included in this study. N. Kocer RESULTS: We observed objective CSF leakage in 64 of 85 patients (75%). The CSF leak was located C. Islak in the ethmoidal region in 37 patients (58%), in the superior wall of the sphenoid sinus in 8 patients (13%), in the posterior wall of the frontal sinus in 10 patients (15%), in the superior wall of the mastoid air cells in 6 patients (9%), and from the skull base into the infratemporal fossa in 1 patient (2%). Two patients (3%) showed leakage into Ͼ1 paranasal sinus. CONCLUSIONS: MR cisternography after the intrathecal administration of gadopentate dimeglumine represents an effective and minimally invasive method for evaluating suspected CSF fistulas along the skull base. It provides multiplanar capabilities without risk of radiation exposure and is an excellent approach to depict the anatomy of CSF spaces and CSF fistulas. SF leakage implies abnormal communication between the using this technique.19,20 In addition, the combination of CT Csubarachnoid space and the nasal or middle ear cavity.
    [Show full text]
  • Pharmacologyonline 2: 727-753 (2010) Ewsletter Bradu and Rossini
    Pharmacologyonline 2: 727-753 (2010) ewsletter Bradu and Rossini COTRAST AGETS - IODIATED PRODUCTS. SECOD WHO-ITA / ITA-OMS 2010 COTRIBUTIO O AGGREGATE WHO SYSTEM-ORGA CLASS DISORDERS AD/OR CLUSTERIG BASED O REPORTED ADVERSE REACTIOS/EVETS Dan Bradu and Luigi Rossini* Servizio Nazionale Collaborativo WHO-ITA / ITA-OMS, Università Politecnica delle Marche e Progetto di Farmacotossicovigilanza, Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Regione Marche, Italia Summary From the 2010 total basic adverse reactions and events collected as ADRs preferred names in the WHO-Uppsala Drug Monitoring Programme, subdivided in its first two twenty years periods as for the first seven iodinated products diagnostic contrast agents amidotrizoate, iodamide, iotalamate, iodoxamate, ioxaglate, iohexsol and iopamidol, their 30 WHO-system organ class disorders (SOCDs) aggregates had been compared. Their common maximum 97% levels identified six SOCDs only, apt to evaluate the most frequent single ADRs for each class, and their percentual normalization profiles for each product. The WILKS's chi square statistics for the related contingency tables, and Gabriel’s STP procedure applied to the extracted double data sets then produced profile binary clustering, as well as Euclidean confirmatory plots. They finally showed similar objectively evaluated autoclassificative trends of these products, which do not completely correspond to their actual ATC V08A A, B and C subdivision: while amidotrizoate and iotalamate, and respectively iohesol and iopamidol are confirmed to belong to the A and B subgroups, ioxaglate behaves fluctuating within A, B and C, but iodamide looks surprizingly, constantly positioned together with iodoxamate as binary/ternary C associated. In view of the recent work of Campillos et al (Science, 2008) which throws light on the subject, the above discrepancies do not appear anymore unexpected or alarming.
    [Show full text]
  • Page 1 Note: Within Nine Months from the Publication of the Mention
    Europäisches Patentamt (19) European Patent Office & Office européen des brevets (11) EP 1 411 992 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 49/04 (2006.01) A61K 49/18 (2006.01) 13.12.2006 Bulletin 2006/50 (86) International application number: (21) Application number: 02758379.8 PCT/EP2002/008183 (22) Date of filing: 23.07.2002 (87) International publication number: WO 2003/013616 (20.02.2003 Gazette 2003/08) (54) IONIC AND NON-IONIC RADIOGRAPHIC CONTRAST AGENTS FOR USE IN COMBINED X-RAY AND NUCLEAR MAGNETIC RESONANCE DIAGNOSTICS IONISCHES UND NICHT-IONISCHES RADIOGRAPHISCHES KONTRASTMITTEL ZUR VERWENDUNG IN DER KOMBINIERTEN ROENTGEN- UND KERNSPINTOMOGRAPHIEDIAGNOSTIK SUBSTANCES IONIQUES ET NON-IONIQUES DE CONTRASTE RADIOGRAPHIQUE UTILISEES POUR ETABLIR DES DIAGNOSTICS FAISANT APPEL AUX RAYONS X ET A L’IMAGERIE PAR RESONANCE MAGNETIQUE (84) Designated Contracting States: (74) Representative: Minoja, Fabrizio AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Bianchetti Bracco Minoja S.r.l. IE IT LI LU MC NL PT SE SK TR Via Plinio, 63 20129 Milano (IT) (30) Priority: 03.08.2001 IT MI20011706 (56) References cited: (43) Date of publication of application: EP-A- 0 759 785 WO-A-00/75141 28.04.2004 Bulletin 2004/18 US-A- 5 648 536 (73) Proprietor: BRACCO IMAGING S.p.A. • K HERGAN, W. DORINGER, M. LÄNGLE W.OSER: 20134 Milano (IT) "Effects of iodinated contrast agents in MR imaging" EUROPEAN JOURNAL OF (72) Inventors: RADIOLOGY, vol. 21, 1995, pages 11-17, • AIME, Silvio XP002227102 20134 Milano (IT) • K.M.
    [Show full text]
  • ACR Manual on Contrast Media
    ACR Manual On Contrast Media 2021 ACR Committee on Drugs and Contrast Media Preface 2 ACR Manual on Contrast Media 2021 ACR Committee on Drugs and Contrast Media © Copyright 2021 American College of Radiology ISBN: 978-1-55903-012-0 TABLE OF CONTENTS Topic Page 1. Preface 1 2. Version History 2 3. Introduction 4 4. Patient Selection and Preparation Strategies Before Contrast 5 Medium Administration 5. Fasting Prior to Intravascular Contrast Media Administration 14 6. Safe Injection of Contrast Media 15 7. Extravasation of Contrast Media 18 8. Allergic-Like And Physiologic Reactions to Intravascular 22 Iodinated Contrast Media 9. Contrast Media Warming 29 10. Contrast-Associated Acute Kidney Injury and Contrast 33 Induced Acute Kidney Injury in Adults 11. Metformin 45 12. Contrast Media in Children 48 13. Gastrointestinal (GI) Contrast Media in Adults: Indications and 57 Guidelines 14. ACR–ASNR Position Statement On the Use of Gadolinium 78 Contrast Agents 15. Adverse Reactions To Gadolinium-Based Contrast Media 79 16. Nephrogenic Systemic Fibrosis (NSF) 83 17. Ultrasound Contrast Media 92 18. Treatment of Contrast Reactions 95 19. Administration of Contrast Media to Pregnant or Potentially 97 Pregnant Patients 20. Administration of Contrast Media to Women Who are Breast- 101 Feeding Table 1 – Categories Of Acute Reactions 103 Table 2 – Treatment Of Acute Reactions To Contrast Media In 105 Children Table 3 – Management Of Acute Reactions To Contrast Media In 114 Adults Table 4 – Equipment For Contrast Reaction Kits In Radiology 122 Appendix A – Contrast Media Specifications 124 PREFACE This edition of the ACR Manual on Contrast Media replaces all earlier editions.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Injection of Contrast Media V7 – 2010 13 5
    ACR Manual on Contrast Media Version 8 2012 ACR Committee on Drugs and Contrast Media ACR Manual on Contrast Media Version 8 2012 ACR Committee on Drugs and Contrast Media © Copyright 2012 American College of Radiology ISBN: 978-1-55903-009-0 Table of Contents Topic Last Updated Page 1. Preface. V8 – 2012 . 3 2. Introduction . V7 – 2010 . 4 3. Patient Selection and Preparation Strategies . V7 – 2010 . 5 4. Injection of Contrast Media . V7 – 2010 . 13 5. Extravasation of Contrast Media . V7 – 2010 . 17 6. Adverse Events After Intravascular Iodinated Contrast Media . V8 – 2012 . 21 Administration 7. Contrast Media Warming . V8 – 2012 . 29 8. Contrast-Induced Nephrotoxicity . V8 – 2012 . 33 9. Metformin . V7 – 2010 . 43 10. Contrast Media in Children . V7 – 2010 . 47 11. Iodinated Gastrointestinal Contrast Media in Adults: Indications . V7 – 2010 . 55 and Guidelines 12. Adverse Reactions to Gadolinium-Based Contrast Media . V7 – 2010 . 59 13. Nephrogenic Systemic Fibrosis (NSF) . V8 – 2012 . 63 14. Treatment of Contrast Reactions . V8 – 2012 . 73 15. Administration of Contrast Media to Pregnant or Potentially . V6 – 2008. 75 Pregnant Patients 16. Administration of Contrast Media to Breast-Feeding Mothers . V6 – 2008 . 79 Table 1 – Indications for Use of Iodinated Contrast Media . V6 – 2008 . 81 Table 2 – Organ or System-Specific Adverse Effects from the Administration . V7 – 2010 . 82 of Iodine-Based or Gadolinium-Based Contrast Agents Table 3 – Categories of Reactions . V7 – 2010 . 83 Table 4 – Management of Acute Reactions in Children . V7 – 2010 . 84 Table 5 – Management of Acute Reactions in Adults . V6 – 2008 . 86 Table 6 – Equipment for Emergency Carts . V6 – 2008 .
    [Show full text]
  • OSMOVIST Iotrolan Injection
    PRODUCT MONOGRAPH ® OSMOVIST Iotrolan Injection ® OSMOVIST 240 Iotrolan Injection 240 mg I/mL ® OSMOVIST 300 Iotrolan Injection 300 mg I/mL Dimeric Non-ionic Radiographic Contrast Medium For Myelography Bayer Inc. Date of Preparation: 77 Belfield Road April 11, 2007 Toronto, Ontario M9W 1G6 Canada www.bayer.ca Submission Control No.: 113334 © 2007, Bayer Inc. PRODUCT MONOGRAPH OSMOVIST® Iotrolan injection ® OSMOVIST 240 Iotrolan injection 240 mg I/mL ® OSMOVIST 300 Iotrolan injection 300 mg I/mL THERAPEUTIC CLASSIFICATION A Dimeric Non-ionic Radiographic Contrast Medium For Myelography ACTION and CLINICAL PHARMACOLOGY OSMOVIST (iotrolan) is a dimeric, non-ionic, hexaiodinated radiocontrast medium. The contrast-giving substance, iotrolan, is a dimer of triiodinated isophthalic acid derivatives, in which the firmly bound iodine absorbs the X-rays. Solutions of OSMOVIST 240 mg I/mL and 300 mg I/mL are isotonic to plasma and cerebrospinal fluid at radiologically useful iodine levels. After intrathecal administration, iotrolan is absorbed from cerebrospinal fluid (CSF) into the blood stream. The mean half-life of the transfer of iotrolan from the spinal fluid to the blood plasma was found to be 5.7 ± 6.0 hours in adults. The highest concentration of iodine in plasma occurred 3.5 ± 3.1 hours after intrathecal administration. Plasma protein binding at a concentration of 1.2 mg I/mL is 2.4%. The mean elimination half- Page 2 life of iotrolan in the plasma is 13.6 ± 13.9 hours (median of 9 hours). Approximately 50- 80% of the administered dose is excreted unmetabolized by the kidneys within 24 hours after administration, and approximately 90% within 72 hours.
    [Show full text]
  • Contrast Agents in Pediatric Neuroimaging
    Contrast Agents in Pediatric Neuroimaging Sylvester Chuang1 From the Hospital for Sick Children, Toronto, Ontario During the last two decades the development which substitutions are made at the acid group. of contrast agents for myelography, angiography, Examples of common contrast agents used in computed tomography (CT) and magnetic reso­ North America are listed in Table 1. nance imaging (MR) has been remarkable. What Recent developments have all centered on the follows is a review of contrast agents used in nonionic contrast agents, because these are less neuroradiology-specifically, the ionic and non­ toxic than the ionics (1); however, the cost of the ionic contrast agents for radiographic/CT proce­ nonionics is significantly higher than that of the dures, and the paramagnetic contrast agents used ionics. Despite the debate regarding the cost in MR studies. Topics covered are the indications effectiveness of the nonionics (2-9), we routinely for and use of contrast agents, doses and com­ use nonionic contrast agents for all radiologic parisons, complications and cost benefits, and investigations at the Hospital for Sick Children in what the future of contrast media might hold. Toronto. We do so because of the lower compli­ cation rate, although there is no convincing evi­ Iodinated Contrast Agents dence of any decrease in the mortality rate. Nevertheless, when there is extravasation of con­ The basic structure of iodinated contrast trast into the tissue on IV injection, the morbidity agents is the benzene ring (Fig. 1), with its at­ is lower. tached iodine atoms. The remaining components Elimination of contrast agents is dependent on are the acid group and organic substitutes which organic substitutions.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,281,515 B1 Demeo Et Al
    USOO6281515B1 (12) United States Patent (10) Patent No.: US 6,281,515 B1 Demeo et al. (45) Date of Patent: Aug. 28, 2001 (54) LIGHTWEIGHT RADIATION PROTECTIVE 5,140,710 8/1992 Rademacher. GARMENTS 5.245,195 9/1993 Shah et al. ........................ 250/515.1 5,446,925 9/1995 Baker et al. (75) Inventors: Ronald Demeo, Miami Beach; Marcus SE2- 1-2 : 3.E. SRaCWalacle al. ....................... 250/519.1 into North Miami Beach, both of 5,525,408 6/1996 Weir et al. 5,856,415 1/1999 Lagace et al.. (73) Assignee: Meridian Research and Development, * cited by examiner POmpano Beach,Beacn, FL (US)(US Primary Examiner Jack Berman (*) Notice: Subject to any disclaimer, the term of this ASSistant Examiner—Johnnie L. Smith, II patent is extended or adjusted under 35 (74) Attorney, Agent, or Firm Townsend and Townsend U.S.C. 154(b) by 0 days. and Crew LLP, Guy W. Chambers, Esq. (57) ABSTRACT (21) Appl. No.: 09/206,671 A lightweight,9. 9. breathable garment9. which has radiopaquepad (22) Filed: Dec. 7, 1998 qualities and a method for making the radiopaque garment. (51) Int. CI.7 B21F 3/02 In a preferred embodiment, a lightweight fabric, Such as a (52)52) U. s C-rry - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 250/516.1 iscloth impregnated Surgical mask with liner a lightweight (24) or an entire radiopaque Surgical compound, mask (10), (58) Field of Search .............................. 259515.1; 519.1, Such as a barium Sulfate compound, to impart radiopaque 250/516.1; 428/551 qualities. Impregnation of the lightweight radiopaque com pound can be performed in any number of ways including (56) References Cited Soaking the fabric in a Solution containing the lightweight U.S.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Lohexol Versus Metrizamide for Lumbar Myelography: Double-Blind Trial
    181 lohexol versus Metrizamide for Lumbar Myelography: Double-Blind Trial Trygve O. Gabrielsen' Lumbar myelography was performed in 50 patients; 25 received iohexol (an investi­ Stephen S. Gebarski' gational aqueous contrast agent) and 25 received metrizamide. The two media produced James E. Knake' radiographs of equal quality. However, iohexol is stable in solution, while metrizamide Joseph T. Latack' is not. Further, markedly less morbidity resulted from iohexol. These features indicate Peter J. Yang' that iohexol may be superior to metrizamide as a contrast agent for lumbar myelography. Julian T. Hoff2 Aqueous contrast materials have several well known advantages over oily and gaseous agents for lumbar myelography [1], and metrizamide is the best of the water-soluble contrast agents licensed by the Food and Drug Administration for lumbar myelography [2-6]. The development of this agent represented an important advance, but it is not ideal. Troublesome qualities of metrizamide include high cost; an unwieldy stable state (lyophilized powder); and transient side effects such as headache, nausea, vomiting, dizziness, meningeal irritation, fever , painful paresthe­ sias in the legs, myoclonic leg spasms, seizures, confusion or other abnormal psychic states including hallucinations, affective lability, agitation, impaired memory, asterixis, global aphasia, and cortical blindness [1-5]. lohexol (N ,N' -bis(2,3-dihydroxypropyl)-5-[N-(2,3-dihydroxypropyl)acetamido]- 2,4,6-triiodoisophthalamide) is another water-soluble, nonionic, isotonic contrast medium also developed by Nyegaard, Oslo, Norway, and tested and distributed in the United States by Winthrop Labs ., New York, NY. Extensive laboratory investi­ gations and early clinical trials have indicated that iohexol appears to be superior to metrizamide for intrathecal application [7-9].
    [Show full text]
  • Manual on Contrast Media Version 7 2010
    MANUAL ON CONTRAST MEDIA VERSION 7 2010 Quality is our Image™ Table of Contents TOPIC Preface ............................................................................................................................... Introduction ....................................................................................................................... Patient Selection and Preparation Strategies ...................................................................... Injection of Contrast Media ................................................................................................ Extravasation of Contrast Media ....................................................................................... Incidence of Adverse Effects .............................................................................................. Adverse Effects of Iodinated Contrast Media .................................................................... Contrast Nephrotoxicity ..................................................................................................... Metformin ........................................................................................................................ Contrast Media in Children ............................................................................................... Iodinated Gastrointestinal Contrast Media: Indications and Guidelines ............................. Adverse Reactions to Gadolinium-Based Contrast Media ................................................. Nephrogenic Systemic Fibrosis
    [Show full text]